Bavarian Nordic — August 2016
-
Yesterday’s Q2 report for Bavarian Nordic, which was actually better than we expected,
was of less importance than news about its product pipeline, with PROSTVAC
as a parcular point of interest. The second interim analysis was successfully passed
and we are now waing for the final results, which are expected mid-2017. This
means our analyst postpones the potenal launch unl 2018 (2017) and on the back
of some other adjustments he nudges down the share price target from 410 to 394. -
We connue to like the investment case yet highlight that we expect the investment
case to be rather volale and only for investors with a high degree of risk tolerance. -
Nordea har dermed sænket kursmålet 16 kr
-
Danske Bank fastholder derimod Buy og kursmål 404 kr
-
Af en eller anden grund er der faldet bogstaver ud i den tekst jeg har kopieret. Men det kan læses alligevel
-
-
Ja som jeg ser det er det vel at tage en evt tur med ned og samle den op eller ud af aktien mandag morgen.
-
Det er ikke en afvisning. Der spørges på yderligere information om pennen. Det var delvist ventet. I hverfald af skarpe Novod fra Nordea.
-
Et pænt fald.
-
Vi skal nok ikke forvente noget fra FDA før i November. Det bliver meget spændende at høre Zealands kommentarer til dette den 2. september.
-
Den kursmæssige reaktion er vel som forventet.
-
Lige nu er der stor købsiver omkring 110.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind